Revelation Biosciences, Inc.
Revelation Biosciences, Inc.
- Market cap
- $27.25K
Your view on REVBW
Overview
What the company does, where it operates, and who runs it.
About Revelation Biosciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- James Rolke
- Headquarters
- 4660 La Jolla Village Drive, San Diego, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- James Rolke
- Headquarters
- 4660 La Jolla Village Drive, San Diego, CA, US
Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering immunology-based therapies and diagnostic tools aimed at preventing and treating a range of illnesses.
Their flagship therapeutic, REVTx-99, is an intranasal immunomodulator designed to both prevent and treat a broad spectrum of respiratory viral infections, including SARS-CoV-2 (and its variants), influenza A and B, parainfluenza, rhinovirus, and RSV. Furthermore, its potential extends to addressing allergic rhinitis and chronic nasal congestion.
The company's pipeline also includes REVTx-200, an intranasal immunomodulator intended as an adjunct to enhance the efficacy of intramuscular vaccinations, thereby boosting immunity. Additionally, they are developing REVDx-501, a rapid diagnostic test designed for convenient home use to detect respiratory viral infections.
Established in 2019, the company is headquartered in New York, New York.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Revelation Biosciences, Inc.. Starting points for Revelation Biosciences, Inc.: EPS -$21.73, beta -0.12 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Revelation Biosciences, Inc.. Trailing twelve-month EPS for Revelation Biosciences, Inc. stands at -$21.73. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Revelation Biosciences, Inc.. Revelation Biosciences, Inc. has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| BVNRYBavarian Nordic A/S | Healthcare | OTC | $2.4B | ||
| BXPHFBotanix Pharmaceuticals Limited | Healthcare | OTC | $89.0M | ||
| ARUXFAcrux Limited | Healthcare | OTC | $1.8M | ||
| ARVNArvinas, Inc. | Healthcare | NASDAQ | $423.0M | ||
| ARWRArrowhead Pharmaceuticals, Inc. | Healthcare | NASDAQ | $5.8B | ||
| ASBPAspire Biopharma Holdings, Inc. | Healthcare | NASDAQ | $822,602 | ||
| ASBPWAspire Biopharma Holdings, Inc. | Healthcare | NASDAQ | $121,920 | ||
| ASCLFAscletis Pharma Inc. | Healthcare | OTC | $2.1B | ||
| ASEP.CNAsep Medical Holdings Inc | Healthcare | CNQ | — | ||
| ASMBAssembly Biosciences, Inc. | Healthcare | NASDAQ | $454.4M | ||
| ASNDAscendis Pharma A/S | Healthcare | NASDAQ | $16.6B | ||
| ASPEAspen Neuroscience Inc. | Healthcare | NASDAQ | $361.2M | ||
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Revelation Biosciences, Inc., and how their positions are changing. At a $27,251 market value, institutional positions materially move Revelation Biosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Revelation Biosciences, Inc. executives and directors. Shares of Revelation Biosciences, Inc. have traded between $0.0098 and $0.01 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Revelation Biosciences, Inc.. Coverage tracks Revelation Biosciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Revelation Biosciences, Inc.